26714 Federal Register / Vol. 74, No. 105 / Wednesday, June 3, 2009 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Cancer 

Prevention Research Small Grant Program. 

Date: June 15–16, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Renaissance M Street Hotel, 1143 

New Hampshire Avenue, NW., Washington, 

DC 20037. 

Contact Person: Irina Gordienko, PhD, 

Scientific Review Officer, Scientific Review 

and Logistics Branch, Division of Extramural 

Activities, National Cancer Institute, NIH, 

6116 Executive Blvd., Rm. 7073, Bethesda, 

MD 20892, 301–594–1566, 

gordienkoiv@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control; 93.701, ARRA Related 

Biomedical Research and Research Support 

Awards, National Institutes of Health, HHS) 

Dated: May 26, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–12879 Filed 6–2–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Clinical Center; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the Board 

of Scientific Counselors of the NIH 

Clinical Center. The meeting will be 

closed to the public as indicated below 

in accordance with the provisions set 

forth in section 552b(c)(6), Title 5 

U.S.C., as amended for the review, 

discussion, and evaluation of individual 

intramural programs and projects 

conducted by the Clinical Center, 

including consideration of personnel 

qualifications and performance, and the 

competence of individual investigators, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Board of Scientific 

Counselors of the NIH Clinical Center. 

Date: June 18, 2009. 

Time: 8:15 a.m. to 5:30 p.m. 

Agenda: To review and evaluate the 

Clinical Center’s Nursing Department. 

Place: National Institutes of Health, 

Building 10, 10 Center Drive, Room 4–2551, 

Bethesda, MD 20892. 

Contact Person: David K Henderson, MD, 

Deputy Director for Clinical Care, Office of 

the Director, Clinical Center, National 

Institutes of Health, Building 10, Room 6– 

1480, Bethesda, MD 20892, (301) 496–3515. 

Dated: May 26, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–12877 Filed 6–2–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Biomedical 

Imaging and Bioengineering; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Biomedical Imaging and Bioengineering 

Special Emphasis Panel—Health Disparities. 

Date: June 25, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott Suites, 6711 

Democracy Blvd., Bethesda, MD 20817. 

Contact Person: Ruth Grossman, DDS, 

Scientific Review Officer, National Institutes 

of Biomedical Imaging and Bioengineering, 

6707 Democracy Boulevard, Room 960, 

Bethesda, MD 20892, 301–496–8775, 

grossmanrs@mail.nih.gov. 

Dated: May 26, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–12875 Filed 6–2–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: Use of N-AcetylMannosamine and Derivatives Thereof 

to Treat Muscle Wasting Diseases and 

Kidney Diseases Related to 

Hyposialylation 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

404.7(a)(1)(i), that the National 

Institutes of Health, Department of 

Health and Human Services, is 

contemplating the grant of an exclusive 

patent license to practice the inventions 

embodied in U.S. Patent Application 

No. 60/932,451, filed May 31, 2007, now 

abandoned, [HHS Ref. No. E–217–2007/ 

0–US–01]; PCT Patent Application No. 

PCT/US2008/006895, filed May 30, 

2008, [HHS Ref. No. E–217–2007/0– 

PCT–02], both of which are entitled, ‘‘NAcetyl-Mannosamine as a Therapeutic 

Agent’’ (Inventors: Drs. Marjan Huizing, 

William A. Gahl, Irini Manoli, and 

Enriko Klootwijk, NHGRI) to New 

Zealand Pharmaceuticals, Ltd., having 

an office in at Palmerston North, New 

Zealand. The patent rights in these 

inventions have been assigned to the 

United States of America. 

The prospective exclusive license 

territory may be worldwide, and the 

field of use may be limited to the use 

of N-Acetyl-Mannosamine or derivatives 

thereof for the treatment of muscle 

wasting diseases and kidney diseases 

related to hyposialylation. 

DATES: Only written comments and/or 

applications for a license which are 

received by the NIH Office of 

Technology Transfer on or before 

August 3, 2009 will be considered. 


PWALKER on PROD1PC71 with NOTICES
Federal Register / Vol. 74, No. 105 / Wednesday, June 3, 2009 / Notices 26715 

ADDRESSES: Requests for copies of the 

patent application, inquiries, comments, 

and other materials relating to the 

contemplated exclusive license should 

be directed to: Steven Standley, PhD, 

Licensing and Patenting Manager, Office 

of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, MD 

20852–3804; Telephone: (301) 435– 

4074; Facsimile: (301) 402–0220; E-mail: 

sstand@od.nih.gov. 

SUPPLEMENTARY INFORMATION: N-Acetyl 

Mannosamine is a precursor for the 

synthesis of sugar molecules known as 

sialic acids which play an important 

role in specific biological processes 

such as cellular adhesion, cellular 

communication and signal transduction. 

Lack of sialic acids also play an 

important role in disease processes such 

as cancer, inflammation and immunity. 

This invention relates to methods of 

administering N-Acetyl Mannosamine 

or its derivative (to produce sialic acid 

in patients who are deficient in the 

sugar molecule) to treat muscular 

atrophy including hereditary inclusion 

body myopathy (HIBM) and distal 

myopathy with rimmed vacuoles 

(DMRV, or Nonaka myopathy). Certain 

kidney conditions such as those arising 

from hyposialytion of kidney 

membranes may be treated by this 

method as well. 

The prospective exclusive license will 

be royalty bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR 404.7. The prospective 

exclusive license may be granted unless 

within sixty (60) days from the date of 

this published notice, the NIH receives 

written evidence and argument that 

establishes that the grant of the license 

would not be consistent with the 

requirements of 35 U.S.C. 209 and 37 

CFR 404.7. 

Applications for a license in the field 

of use filed in response to this notice 

will be treated as objections to the grant 

of the contemplated exclusive license. 

Comments and objections submitted to 

this notice will not be made available 

for public inspection and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: May 27, 2009. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E9–12858 Filed 6–2–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Office of the Secretary 

[Docket No. DHS–2009–0012] 

Privacy Act of 1974, as Amended; 

Computer Matching Program 

(Department of Homeland Security 

United States Citizenship and 

Immigration Services (DHS/USCIS)- 

New Jersey Department of Labor and 

Workforce Development (NJLWD)) 

AGENCY: United States Citizenship and 

Immigration Services, DHS. 

ACTION: Notice of the renewal of an 

existing computer matching program, 

which is scheduled to expire on July 6, 

2009. 

SUMMARY: In accordance with the 

provisions of the Privacy Act, as 

amended, this notice announces the 

renewal of a computer matching 

program that Department of Homeland 

Security United States Citizenship and 

Immigration Services (DHS/USCIS) is 

currently conducting with New Jersey 

Department of Labor and Workforce 

Development. 

DATES: The matching program will 

become effective 30 days after 

publication of this notice in the Federal 

Register. The matching program will 

continue for 18 months from the 

effective date and may be extended for 

an additional 12 months thereafter, if 

certain conditions are met. 

ADDRESSES: Interested parties may 

comment on this notice by either 

telefaxing to (703) 483–2999 or writing 

to the Privacy Office, Department of 

Homeland Security, Washington, DC 

20528. All comments received will be 

available for public inspection at this 

address. 

FOR FURTHER INFORMATION CONTACT: For 

general questions please contact Donald 

Hawkins (202–272–8000), USCIS 

Privacy Officer, 20 Massachusetts 

Avenue, NW., Washington, DC 20529. 

For privacy issues please contact: Mary 

Ellen Callahan (703–235–0780), Chief 

Privacy Officer, Privacy Office, U.S. 

Department of Homeland Security, 

Washington, DC 20528. 

SUPPLEMENTARY INFORMATION: 

A. General 

The Computer Matching and Privacy 

Protection Act of 1988 (Public Law 

(Pub. L.) 100–503), amended the Privacy 

Act (5 U.S.C. 552a) by describing the 

conditions under which computer 

matching involving the Federal 

government could be performed and 

adding certain protections for 

individuals applying for, and receiving, 

Federal benefits. Section 7201of the 

Omnibus Budget Reconciliation Act of 

1990 (Pub. L. 101–508) further amended 

the Privacy Act regarding protections for 

such individuals. 

The Privacy Act, as amended, 

regulates the use of computer matching 

by Federal agencies when records in a 

system of records are matched with 

other Federal, State, or local government 

records. It requires Federal agencies 

involved in computer matching 

programs to: 

(1) Negotiate written agreements with 

the other agency or agencies 

participating in the matching programs; 

(2) Obtain the approval of the 

matching agreement by the Data 

Integrity Boards (DIB) of the 

participating Federal agencies; 

(3) Publish notice of the computer 

matching program in the Federal 

Register; 

(4) Furnish detailed reports about 

matching programs to Congress and 

OMB; 

(5) Notify applicants and beneficiaries 

that their records are subject to 

matching; and 

(6) Verify match findings before 

reducing, suspending, terminating, or 

denying an individual’s benefits or 

payments. 

B. DHS Computer Matches Subject to 

the Privacy Act 

DHS/USCIS has taken action to 

ensure that all of DHS’s computer 

matching programs comply with the 

requirements of the Privacy Act, as 

amended. 

C. Purpose of the Matching Program 

The purpose of this agreement is to 

provide the NJLWD with electronic 

access to immigration status information 

contained within DHS/USCIS’ 

Verification Information System (VIS). 

This access will enable the NJLWD to 

determine whether an applicant is 

eligible for benefits under the 

Unemployment Compensation (UC) 

program administered by NJLWD. 

D. Authority for Conducting the 

Matching Program 

NJLWD seeks access to the 

information contained in the DHS– 

USCIS VIS database to execute its 

obligations under Section 1137 of the 

Social Security Act and New Jersey 

Statute 43:21–4. 

USCIS maintains the VIS database 

pursuant to Section 121 of the 

Immigration Reform and Control Act 

(IRCA) of 1986, Public Law 99–603, as 

amended by the Personal Responsibility 

and Work Opportunity Reconciliation 


PWALKER on PROD1PC71 with NOTICES